The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Inclusion Criteria:

• Diagnosis of MG confirmed by:

  • History of a positive serologic test for anti-AChR antibodies, and

  • One of the following:

    • History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation
    • History of positive anticholinesterase test (e.g., edrophonium chloride test); or
    • Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician

• Disease duration from MG onset ≤ 3 years before T-4 (Enrolment);

• MGFA class IIb to IV;

• Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria

• Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.

Exclusion Criteria:

• Patient unable to understand and sign the informed consent
• Hypersensitivity to the active substance or to any of the excipients of the study product
• Patient for whom the study product is contraindicated according to SmPC
• Previous treatment with C5 inhibitors
• Last rituximab infusion performed < 6 months before T-4 (Enrolment)
• Last infusion with FcRn blockers performed < 3 months before T-4 (Enrollment)
• Pregnant or lactating or planning a pregnancy during the study
• Patient who plan to relocate during the study
• Patient who are unsure of following the visit schedule
• Patient unable to complete questionnaires
• Previous or current participation to other interventional studies

Patients with anti-AChR antibody positive, generalized, myasthenia gravis elegible to Ravulizumab treatment with a disease duration from onset equal or less than 3 years.

Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.